

27 July 2016

Quarterly Review

Highlights

- EVE completed first tranche investment into Omniblend Innovation, a ~25% stake, increasing to ~40%
- Omniblend Innovation has engaged OHC to progress Scandinavian distribution agreements
- Marketing activities for Faulding GlucoControl™ ramping up in the second half of the year
- Mr Philip Owens appointed as Director – Sales & Marketing for Omniblend Innovation

EVE Investments (ASX:EVE), an ASX listed technology investment company, has today released its Appendix 4C Report for the three month period to 30 June 2016 and is pleased to provide a review of its progress for the quarter.

Product Launch

On May 2, Omniblend Innovation and Faulding held a joint product launch. Victorian MP for Broadmeadows and Parliamentary Secretary for Medical Research was in attendance to help launch Omniblend Innovation's flagship product GlucoControl™. The drink is being distributed first in Australia by leading healthcare solution provider Faulding as GlucoControl™ and is available now at Chemmart pharmacy and other independent pharmacies.

“When we first heard about this product we recognised its potential right away,” said **Andrew Vidler**, General Manager Endeavour Consumer Health.

“We're thrilled to have partnered with Omniblend Innovation and its food technology innovators to make Faulding GlucoControl more accessible for Australian consumers and believe it will have a positive impact on people wanting to reduce meal GI levels.”

Exclusive Engagement Signed with OHC for Scandinavian Territories

Omniblend Innovation (“OI”) engaged Oskar Hakansson Consulting (“OHC”) to provide Omniblend Innovation with assistance in licensing opportunities in Scandinavian countries. OHC will identify, negotiate and contract exclusive supply of Omniblend Innovation's clinically-validated natural pre-meal drink for those with type 2 diabetes (T2D) and pre-diabetes, with partners and distributors in Sweden, Denmark, Norway and Finland for an exclusive period of two years.

Additionally, Omniblend Innovation continues to progress negotiations with potential distributors in the United States, China and the United Kingdom.

Manufacturing and Distribution Momentum

A second large manufacturing order for Faulding GlucoControl™ was received in the quarter, providing additional volume of stock for distribution into selected pharmacies. This second production will increase the availability of the product in pharmacy outlets across Australia and coincides with marketing programs designed to build product and brand awareness.

Marketing Programs

Omniblend Innovation in conjunction with Faulding announced that it will shortly be commencing an active marketing campaign for Faulding GlucoControl™ that will incorporate print, radio and television media. Omniblend Innovation is continuing to present the product at various conferences and industry related seminars,

including the Australia-China Complementary Health Products Expo 2016, which was held in Melbourne in late June.

Promotional and Educational 'Diet for Diabetes' Seminars

As part of its marketing program, Omniblend Innovation held a promotional information session at the University of WA on 30 May 2016. The event included a panel discussion and Q&A session and was presented by Professor Peter Clifton, a prominent endocrinologist and Professor of Nutrition at the University of South Australia. A second event was held in Melbourne on 12 July which included Dr Ross Walker, one of Australia's leading preventative health experts who has a weekly radio show on 2UE.



Picture 1: Professor Peter Clifton from the University of South Australia, presenting at the 'Diets for Diabetes' evening

Further seminars are planned to be held in the coming months in Sydney, Brisbane, Gold Coast and Adelaide.

Further Validation through Ongoing Clinical Trials

A number of additional clinical trials are being conducted in Australia, which involve the Fauling GlucoControl™ product, funded under grants won by the respective universities conducting the trials. These include the Centre of Research Excellence in Translating Nutritional Science to Good Health Trial and the Deakin University Trial.

Interim results from the Centre of Research Excellence trial, which has already reached its halfway point, will be presented publicly for the first time at a forthcoming European Association for the Study of Diabetes (EASD) conference in Munich in September 2016.

Appointment of Mr Philip Owens

In early July, Omniblend Innovation appointed Mr Philip Owens (B.Sc., Grad Dip Psych.) to the position of Director of Sales & Marketing. Mr Owens brings over 20 years of operational and strategic leadership experience to Omniblend Innovation.

Mr Owens has launched and incubated businesses around the globe and has a demonstrable track record of creating exceptional business strategies, structures, processes and results, including doubling an established business to more than \$2 billion (AUD) in sales.

With a breadth of operational and strategic business leadership experience, executive education across three continents and degrees in Neurophysiology and Psychology; Mr Owens has the skills, experience and capability to drive Omniblend Innovation's marketing strategy and commercialisation of its core assets.

Mr Owens has worked in a variety of roles in the health industry, notably ten years with Bayer Health Care in various roles. From 2008 to 2010, he was the Global Brand Team Leader based in Germany. During his time in the role he successfully oversaw global P&L targets, including exceeding sales of 1.2 Billion Euros, managed a marketing budget of 300 Million Euros and a research and development budget of 56 Million Euros.

Since 2011 he has run a private consulting company with a large client base across multiple industries. Mr Owens will commence on a part-time basis immediately and shift to a full-time role in September.

Settlement

During the quarter, EVE announced that the Tranche 1 investment in Omniblend Innovation had been settled, giving EVE an approximately 25% stake. EVE will increase its interest in the Company to ~40% by 30 September 2016, under the revised payment terms for the tranche 2 investment (see ASX announcement on 1 April 2016).

New Investment Opportunities

EVE continues to review Australian and international technology investment opportunities across a broad range of sub-sectors including medtech, agtech, fintech, health & wellness, social, gaming, payments and cyber security.

General Meeting

On 31 May, EVE held a General Meeting of shareholders. The meeting was called to ratify a prior placement and for the issue of incentive performance rights. All resolutions passed on a show of hands.

Other Investments

EVE has a 35% interest in Wayland Copper, which holds the Ballek copper-gold in Northern Sweden. Beowulf Mining Plc, the joint venture partner/manager of the project, is currently conducting a review of the project. EVE also holds an approximately 30% interest in UK incorporated Agricola Resources Plc. Agricola is intending to undergo a corporate restructure and is seeking a new project.

For more information:

Bill Fry

Executive Director

+61 8 6465 5500

billf@eveinvestments.com.au

About EVE Investments

EVE Investment is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity

EVE INVESTMENTS LTD

ABN

89 106 523 611

Quarter ended ("current quarter")

30 June 2016

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$'000	Year to date (12 months) \$'000
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) staff costs	(84)	(298)
	(b) advertising and marketing	(8)	(41)
	(c) research and development	-	-
	(d) leased assets	-	-
	(e) other working capital	(32)	(287)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other	-	-
	Net operating cash flows	(124)	(626)
Cash flows related to investing activities			
1.8	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	(1,625)	(1,625)
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	(53)
1.9	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Loans to other entities	-	-
1.11	Loans repaid by other entities	-	-
1.12	Other (provide details if material)	-	-
	Net investing cash flows	(1,625)	(1,678)
1.13	Total operating and investing cash flows	(1,749)	(2,304)

1.13	Total operating and investing cash flows (carried forward)	(1,749)	(2,304)
	Cash flows related to financing activities		
1.14	Proceeds from issues of shares, options, etc.	-	2,732
1.15	Proceeds from sale of forfeited shares	-	-
1.16	Proceeds from borrowings	-	-
1.17	Repayment of borrowings	-	-
1.18	Dividends paid	-	-
1.19	Other (costs of issue)	(26)	(172)
	Other (in-specie of subsidiary)	-	(66)
	Net financing cash flows	(26)	2,494
	Net increase (decrease) in cash held	(1,775)	190
1.20	Cash at beginning of quarter/year to date	2,108	138
1.21	Exchange rate adjustments to item 1.20	-	4
1.22	Cash at end of quarter	332	332

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$'000
1.24	Aggregate amount of payments to the parties included in item 1.2	84
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions:

Payments include director fees, administration staff and provision of a fully serviced office by related party entities.

Non-cash financing and investing activities

2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows	Nil
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest	Nil

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$'000	Amount used \$'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$'000	Previous quarter \$'000
4.1 Cash on hand and at bank	332	2,108
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other	-	-
Total: cash at end of quarter (item 1.22)	332	2,108

Acquisitions and disposals of business entities

	Acquisitions (Item 1.8(a))	Disposals (Item 1.9(a))
5.1 Name of entity		
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Steven Jackson
Company Secretary

27 July 2016

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.